MedTrace Logo

NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia

NCT04315987 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-10-28

No results posted yet for this study

Summary

This is phase II study to assess the efficacy of NestaCell® (mesenchymal stem cell) to treat severe COVID-19 pneumonia.

Conditions

Interventions

BIOLOGICAL

NestaCell®

A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.

BIOLOGICAL

Placebo

Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.

Sponsors & Collaborators

  • Cellavita Pesquisa Científica Ltda

    collaborator OTHER

  • Hospital Vera Cruz

    collaborator OTHER

  • Azidus Brasil

    lead INDUSTRY

Principal Investigators

  • Florentino de Araujo Cardoso Filho · Hospital Vera Cruz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04315987 on ClinicalTrials.gov